Search
Sotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigational[L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
Categories: Antihypertensives for Pulmonary Arterial HypertensionProducts: WINREVAIR 45mg Powder and Solvent for Solution for Injection, WINREVAIR 60mg Powder and Solvent for Solution for InjectionTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic
Products: KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL, KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 160MG/VIALVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease
Mixtures: Entyvio 108 mg solution for injection in pre-filled pen, Entyvio 108 mg solution for injection in pre-filled penProducts: ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL, Entyvio 300mg Powder for Concentrate for Solution for InfusionInfliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalThey are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. … It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIAL, REMICADE POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 mg/vialEptinezumab
go.drugbank.com/drugs/DB14040ApprovedInvestigational[F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]
Products: VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML, Vyepti 100 mg/mL concentrate for solution for infusionBotulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigational[A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm … In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.
Products: Powder for Solution for Injection 50 Units/Vial, Powder for Solution for Injection 200 Units/VialRurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalFactor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous
Products: ADYNOVATE 1500IU Powder and Solvent for Solution for Injection, ADYNOVATE 2000IU Powder and Solvent for Solution for InjectionMoroctocog alfa
go.drugbank.com/drugs/DB13999ApprovedMoroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia … Exogenous replacement of Factor VIII is currently the cornerstone of Hemophilia treatment and is used for the prophylaxis and control of bleeding episodes.
Products: Xyntha Powder and Solvent for Solution for Injection 250iu, Xyntha Powder and Solvent for Solution for Injection 500iuParecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalA letter of non-approval for parecoxib was issued by the FDA in 2005. … It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States.
Products: Dynastat Powder for Solution for Injection 40mg, DYNASTAT (POWDER FOR SOLUTION FOR INJECTION 40 MG/2ML)Buserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalBuserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Products: Suprefact Depot - Implantat für 3 Monate